2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/2iy5wruuedsh6.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/00yc7rcvua6a7.js","/_next/static/immutable/chunks/37ktb71aq3480.js","/_next/static/immutable/chunks/2d50b-7eu4558.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/2d6noqpp6ehas.js","/_next/static/immutable/chunks/1sx186c93bpzg.js","/_next/static/immutable/chunks/3dc-1n866s65i.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2w1bvggzb0ga8.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T628,Brentuximab vedotin combined with doxorubicin, vinblastine, and dacarbazine (A-AVD) improves outcomes in advanced-stage classic Hodgkin lymphoma, but patients with a positive early interim PET have inferior prognosis. We evaluated whether very early [ This single-arm, multicentre, phase 2 trial was conducted at 16 centres in seven countries (the Netherlands, Spain, Denmark, Belgium, Portugal, Slovakia, and Poland). Adults aged 18-60 years with previously untreated advanced-stage classic Hodgkin lymphoma, WHO performance status 0-2, and adequate organ function received one cycle of A-AVD (brentuximab vedotin 1·2 mg/kg intravenously, doxorubicin 25 mg/m From Aug 1, 2019, to Aug 31, 2021, we enrolled 150 patients (81 males [54%] and 69 females [46%]; median age 32 years [IQR 23-39]) who received one cycle of A-AVD, after which 90 (60%) of them had a negative PET1 and 60 (40%) a positive result. 145 were evaluable for efficacy; the median follow-up at the clinical cutoff (Sept 1, 2023; database lock Dec 11, 2023) was 30·1 months (IQR 24·6-36·4). 16 patients experienced an mPFS event. The estimated 2-year mPFS was 89·5% (80% CI 85·7-92·4). The most common grade 3-4 adverse event was neutropenia (53 [35%] of 150) followed by anaemia (18 [12%]) and peripheral sensory neuropathy (nine [6%]). Serious adverse events occurred in 45 (30%) of 150 patients. No deaths occurred. Very early PET-guided intensification with BrECADD yields high activity in advanced-stage classic Hodgkin lymphoma while sparing most patients intensive chemotherapy. Takeda Oncology.31:T4bd,While brentuximab vedotin (BV) and radiotherapy (RTx) are established treatment options for CD30-positive cutaneous T-cell lymphoma (CTCL), data on their simultaneous or sequential use regarding efficacy and tolerability remain scarce. In this retrospective analysis, we evaluated the combination of BV and RTx in patients with CD30-positive CTCL. We included 14 CD30-positive CTCL patients from six German cancer centers receiving BV; RTx was initiated within a timeframe of 3 months prior/after BV treatment. RTx was mainly applied as a low-dose scheme. Adverse events of any grade occurred in 71% of patients, most commonly peripheral neuropathy, neutropenia, and radiodermatitis. Thirteen patients achieved a complete or partial remission as best overall response, however, 50% of all patients showed disease progression. At a median follow-up of 14.4 months, median progression-free survival was 12.0 months, with a 1-year rate of 34.0%. The simultaneous or sequential use of RTx during BV treatment was feasible and well tolerated. Future randomized investigations are needed to identify the benefits of this combination treatment regimen as well as adequate dosing of BV and RTx in a prospective manner.32:T625,SummaryBackground and ObjectivesWhile brentuximab vedotin (BV) and radiotherapy (RTx) are established treatment options for CD30‐positive cutaneous T‐cell lymphoma (CTCL), data on their simultaneous or sequential use regarding efficacy and tolerability remain scarce. In this retrospective analysis, we evaluated the combination of BV and RTx in patients with CD30‐positive CTCL.Patients and MethodsWe included 14 CD30‐positive CTCL patients from six German cancer centers receiving BV; RTx was initiated within a timeframe of 3 months prior/after BV treatment. RTx was mainly applied as a low‐dose scheme.ResultsAdverse events of any grade occurred in 71% of patients, most commonly peripheral neuropathy, neutropenia, and radiodermatitis. Thirteen patients achieved a complete or partial remission as best overall response, however, 50% of all patients showed disease progression. At a median follow‐up of 14.4 months, median progression‐free survival was 12.0 months, with a 1‐year rate of 34.0%.ConclusionsThe simultaneous or sequential use of RTx during BV treatment was feasible and well tolerated. Future randomized investigations are needed to identify the benefits of this combination treatment regimen as well as adequate dosing of BV and RTx in a prospective manner.25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"brentuximab vedotin: generic Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on brentuximab vedotin (generic). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/generic/brentuximab%20vedotin\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Generics\",\"item\":\"https://www.reachrx.ai/hub/tag/generic\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"brentuximab vedotin\",\"item\":\"https://www.reachrx.ai/hub/tag/generic/brentuximab%20vedotin\"}]}}"}}]],["$","$L2f",null,{"title":"brentuximab vedotin: Research & Clinical Takeaways","description":"Explore research on brentuximab vedotin (generic) — efficacy, safety, and comparative data.","papers":[{"doi":"10.1111/bjh.70771","pmid":"42629454","title":"BrECADD\n in three days: Implementation of a condensed intensive first‐line regimen in Hodgkin lymphoma","journal_title":"British Journal of Haematology","journal_issn":"0007-1048","published_at":"2026-08-21T00:00:00.000Z","url":"https://doi.org/10.1111/bjh.70771","source_score":13,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-28T06:25:26.326Z","updated_at":"2026-08-28T06:25:26.326Z","tags":[{"paper_doi":"10.1111/bjh.70771","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1111/bjh.70771","tag_type":"brand","value":"Adcetris","value_numeric":null},{"paper_doi":"10.1111/bjh.70771","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1111/bjh.70771","tag_type":"condition","value":"Classic Hodgkin Lymphoma","value_numeric":null},{"paper_doi":"10.1111/bjh.70771","tag_type":"generic","value":"brentuximab vedotin","value_numeric":null},{"paper_doi":"10.1111/bjh.70771","tag_type":"generic","value":"cyclophosphamide","value_numeric":null},{"paper_doi":"10.1111/bjh.70771","tag_type":"generic","value":"dacarbazine","value_numeric":null},{"paper_doi":"10.1111/bjh.70771","tag_type":"generic","value":"dexamethasone","value_numeric":null},{"paper_doi":"10.1111/bjh.70771","tag_type":"generic","value":"doxorubicin","value_numeric":null},{"paper_doi":"10.1111/bjh.70771","tag_type":"generic","value":"etoposide","value_numeric":null},{"paper_doi":"10.1111/bjh.70771","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1111/bjh.70771","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1111/bjh.70771","tag_type":"modality","value":"Antibody-Drug Conjugate","value_numeric":null},{"paper_doi":"10.1111/bjh.70771","tag_type":"modality","value":"Chemotherapy","value_numeric":null},{"paper_doi":"10.1111/bjh.70771","tag_type":"sample_size","value":"n=30","value_numeric":30},{"paper_doi":"10.1111/bjh.70771","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1111/bjh.70771","tag_type":"study_design","value":"Prospective Single-Arm Study","value_numeric":null},{"paper_doi":"10.1111/bjh.70771","tag_type":"warning","value":"Age group tagged as 'adult' based on context (advanced-stage cHL treatment setting); exact age range is not reported in the abstract.","value_numeric":null},{"paper_doi":"10.1111/bjh.70771","tag_type":"warning","value":"Brand name 'Adcetris' used for brentuximab vedotin; confirm local formulary name as branding may vary by region.","value_numeric":null},{"paper_doi":"10.1111/bjh.70771","tag_type":"warning","value":"Median follow-up of 18 months is short for a lymphoma outcomes study; 1-year PFS/OS data should be interpreted cautiously.","value_numeric":null},{"paper_doi":"10.1111/bjh.70771","tag_type":"warning","value":"Study design is described as a feasibility/safety report from a single institution with no comparator arm; 'prospective single-arm study' is inferred as no explicit design label is stated in the abstract.","value_numeric":null}],"summaries":{"what_studied":"Feasibility and safety of a condensed 3-day BrECADD regimen (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone) as first-line therapy in advanced-stage classic Hodgkin lymphoma, reducing IV administration days from 4 to 3 per 21-day cycle across 30 patients treated January 2024–July 2026.","key_result":"Grade ≥3 adverse events occurred in 77% of patients (predominantly haematological); 20% had grade ≥3 infections and 20% had febrile neutropenia. There were no treatment discontinuations, 80% completed only 4 cycles, and 1-year PFS and OS were both 100% at a median follow-up of 18 months.","limitations":"Single-institution, non-comparative study with only 30 patients and short median follow-up of 18 months (range 4–29 months); no randomised control arm to benchmark against standard 4-day BrECADD; long-term durability data are unavailable.","practice_takeaway":"The condensed 3-day BrECADD schedule appears feasible with no treatment discontinuations and a 100% 1-year PFS/OS, but the small single-centre cohort and short follow-up warrant caution before broad adoption. Clinicians should monitor closely for haematological toxicity and infections, which remained common."}},{"doi":"10.1016/s2352-3026(26)00102-x","pmid":"42392109","title":"Autologous and allogeneic haematopoietic cell transplantation in adult patients with Hodgkin lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee and Lymphoma Working Party","journal_title":"The Lancet Haematology","journal_issn":"2352-3026","published_at":"2026-07-02T00:00:00.000Z","url":"https://doi.org/10.1016/s2352-3026(26)00102-x","source_score":27,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-13T17:42:36.195Z","updated_at":"2026-07-13T17:42:36.195Z","tags":[{"paper_doi":"10.1016/s2352-3026(26)00102-x","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00102-x","tag_type":"brand","value":"Adcetris","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00102-x","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00102-x","tag_type":"condition","value":"Hodgkin Lymphoma","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00102-x","tag_type":"condition","value":"Relapsed or Refractory Hodgkin Lymphoma","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00102-x","tag_type":"generic","value":"brentuximab vedotin","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00102-x","tag_type":"generic","value":"carmustine","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00102-x","tag_type":"generic","value":"cyclophosphamide","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00102-x","tag_type":"generic","value":"cytarabine","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00102-x","tag_type":"generic","value":"etoposide","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00102-x","tag_type":"generic","value":"melphalan","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00102-x","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00102-x","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00102-x","tag_type":"modality","value":"Allogeneic Haematopoietic Cell Transplantation","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00102-x","tag_type":"modality","value":"Antibody-Drug Conjugate","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00102-x","tag_type":"modality","value":"Autologous Haematopoietic Cell Transplantation","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00102-x","tag_type":"modality","value":"Checkpoint Inhibitor","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00102-x","tag_type":"modality","value":"Conditioning Regimen","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00102-x","tag_type":"modality","value":"Donor Lymphocyte Infusion","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00102-x","tag_type":"study_design","value":"Clinical Practice Guidelines / Expert Consensus","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00102-x","tag_type":"warning","value":"Sample size tag omitted — this is a guideline paper with no primary patient cohort.","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00102-x","tag_type":"warning","value":"Sex distribution of the target patient population is not reported in the abstract; the sex tag has been omitted.","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00102-x","tag_type":"warning","value":"The abstract does not report formal evidence grading (e.g., GRADE levels) for individual recommendations; the level of evidence tag reflects the consensus/guideline design rather than cited primary studies.","value_numeric":null}],"summaries":{"what_studied":"A panel of 23 experts convened by EBMT developed consensus recommendations on autologous and allogeneic haematopoietic cell transplantation (HCT) for adult patients with relapsed or refractory Hodgkin lymphoma, based on a structured literature review and a 2-day workshop (Sept 29–30, 2025).","key_result":"Key recommendations include: (1) salvage therapy should incorporate brentuximab vedotin and/or checkpoint inhibitors, with metabolic complete response preferred before autologous HCT; (2) BEAM conditioning remains standard; (3) autologous HCT is standard for chemosensitive relapse; (4) allogeneic HCT with reduced-intensity conditioning and post-transplant cyclophosphamide is advised after autologous HCT failure; (5) brentuximab vedotin consolidation is recommended for high-risk patients post-autologous HCT; (6) routine maintenance after allogeneic HCT is not recommended.","limitations":"Consensus-based guideline without formal evidence grading reported in the abstract; recommendations reflect expert opinion synthesized from existing literature rather than new primary trial data.","practice_takeaway":"For relapsed/refractory Hodgkin lymphoma, pursue metabolic complete response with brentuximab vedotin- or checkpoint inhibitor-based salvage before autologous HCT, and use post-transplant cyclophosphamide as GvHD prophylaxis for eligible patients proceeding to allogeneic HCT after autologous failure. Tailor post-allogeneic HCT relapse management individually; routine maintenance is not warranted."}},{"doi":"10.1002/hem3.70422","pmid":"42345030","title":"Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up","journal_title":"HemaSphere","journal_issn":"2572-9241","published_at":"2026-06-23T00:00:00.000Z","url":"https://doi.org/10.1002/hem3.70422","source_score":24,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-27T13:27:37.319Z","updated_at":"2026-06-27T13:27:37.319Z","tags":[{"paper_doi":"10.1002/hem3.70422","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1002/hem3.70422","tag_type":"brand","value":"Adcetris","value_numeric":null},{"paper_doi":"10.1002/hem3.70422","tag_type":"brand","value":"Keytruda","value_numeric":null},{"paper_doi":"10.1002/hem3.70422","tag_type":"brand","value":"Opdivo","value_numeric":null},{"paper_doi":"10.1002/hem3.70422","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1002/hem3.70422","tag_type":"condition","value":"Classic Hodgkin Lymphoma","value_numeric":null},{"paper_doi":"10.1002/hem3.70422","tag_type":"condition","value":"Hodgkin Lymphoma","value_numeric":null},{"paper_doi":"10.1002/hem3.70422","tag_type":"condition","value":"Nodular Lymphocyte-Predominant Hodgkin Lymphoma","value_numeric":null},{"paper_doi":"10.1002/hem3.70422","tag_type":"generic","value":"bleomycin","value_numeric":null},{"paper_doi":"10.1002/hem3.70422","tag_type":"generic","value":"brentuximab vedotin","value_numeric":null},{"paper_doi":"10.1002/hem3.70422","tag_type":"generic","value":"doxorubicin","value_numeric":null},{"paper_doi":"10.1002/hem3.70422","tag_type":"generic","value":"nivolumab","value_numeric":null},{"paper_doi":"10.1002/hem3.70422","tag_type":"generic","value":"pembrolizumab","value_numeric":null},{"paper_doi":"10.1002/hem3.70422","tag_type":"generic","value":"rituximab","value_numeric":null},{"paper_doi":"10.1002/hem3.70422","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1002/hem3.70422","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1002/hem3.70422","tag_type":"modality","value":"Antibody-Drug Conjugate","value_numeric":null},{"paper_doi":"10.1002/hem3.70422","tag_type":"modality","value":"Anti-CD20 Antibody","value_numeric":null},{"paper_doi":"10.1002/hem3.70422","tag_type":"modality","value":"Autologous Stem Cell Transplantation","value_numeric":null},{"paper_doi":"10.1002/hem3.70422","tag_type":"modality","value":"Combination Chemotherapy","value_numeric":null},{"paper_doi":"10.1002/hem3.70422","tag_type":"modality","value":"Involved-Site Radiotherapy","value_numeric":null},{"paper_doi":"10.1002/hem3.70422","tag_type":"modality","value":"PD-1 Inhibitor","value_numeric":null},{"paper_doi":"10.1002/hem3.70422","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1002/hem3.70422","tag_type":"study_design","value":"Clinical Practice Guideline","value_numeric":null},{"paper_doi":"10.1002/hem3.70422","tag_type":"warning","value":"BrECADD (brand: Adcetris-based regimen) is recommended as preferred over eBEACOPP for advanced cHL ≤60 yrs based on HD21 final analysis presented at ASH 2025 (abstract form); full peer-reviewed publication of that final analysis may be pending.","value_numeric":null},{"paper_doi":"10.1002/hem3.70422","tag_type":"warning","value":"N-AVD data in older patients (>60 yrs) comes from a subgroup analysis of SWOG S1826, which enrolled patients aged 12–84 years; direct applicability to older adults should be interpreted with this context.","value_numeric":null},{"paper_doi":"10.1002/hem3.70422","tag_type":"warning","value":"No sample size tag was applied as this is a guideline, not a single study with a defined N.","value_numeric":null},{"paper_doi":"10.1002/hem3.70422","tag_type":"warning","value":"The guideline uses a combined EHA evidence/consensus grading system (e.g., 1A, 2B, 5A); level_of_evidence tag is set to '2' reflecting consensus-based guideline methodology, not a single primary study.","value_numeric":null}],"summaries":{"what_studied":"This EHA Clinical Practice Guideline covers diagnosis, staging, risk-adapted treatment, and follow-up of Hodgkin lymphoma (HL), including classic HL (cHL) across all stages and nodular lymphocyte-predominant HL (NLPHL), in adults of all ages.","key_result":"Key recommendations by stage:\n\n- **Early favorable cHL**: 2× ABVD → 20 Gy IS-RT (standard, regardless of interim PET)\n- **Early unfavorable cHL (≤60 yrs)**: 2× eBEACOPP + 2× ABVD → 30 Gy IS-RT if PET+; no RT if PET− (HD17: 5-yr PFS 97.7% vs. 95.9%)\n- **Advanced cHL (≤60 yrs)**: BrECADD ×4 or ×6 (PET-guided) → IS-RT if PET+ (HD21: 5-yr PFS 93.6% vs. 90.6% for eBEACOPP; 5-yr OS 98% both)\n- **Advanced cHL (>60 yrs)**: N-AVD ×6 preferred (S1826: 3-yr PFS 82% vs. 58% for BV-AVD in older patients)\n- **Relapsed/refractory cHL**: PD-1 inhibitor + chemo → HDCT/ASCT; BV maintenance for high-risk post-ASCT (AETHERA: 5-yr PFS 59% vs. 41%)\n- **Stage IA NLPHL**: 30 Gy IS-RT alone (8-yr PFS 91.9%, OS 99%)","limitations":"- Guideline recommendations vary in evidence level (1A to 5A); several key recommendations rely on retrospective or single-arm Phase II data, especially for older patients and NLPHL.\n- Limited data exist on BrECADD and N-AVD in patients pre-exposed to BV or PD-1 inhibitors in first-line (relevant as these agents move earlier).\n- NLPHL recommendations largely derive from studies that co-enrolled cHL patients, with few prospective NLPHL-specific trials.","practice_takeaway":"For advanced cHL in patients ≤60, BrECADD (PET-guided 4 or 6 cycles) is now the preferred first-line regimen over eBEACOPP, with N-AVD as a less intensive alternative; for patients >60, N-AVD is the standard. In relapsed/refractory cHL, use PD-1 inhibitor–based salvage before HDCT/ASCT whenever accessible, and consider BV maintenance post-ASCT in high-risk patients."}},{"doi":"10.1002/hon.70215","pmid":"42330019","title":"Efficacy and Safety of Novel‐Agent–Based Front‐Line Therapy in Older Adults Aged ≥ 60 Years With Classic Hodgkin Lymphoma: A Systematic Review and Meta‐Analysis","journal_title":"Hematological Oncology","journal_issn":"0278-0232","published_at":"2026-06-22T00:00:00.000Z","url":"https://doi.org/10.1002/hon.70215","source_score":9,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-29T13:22:40.940Z","updated_at":"2026-06-29T13:22:40.940Z","tags":[{"paper_doi":"10.1002/hon.70215","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1002/hon.70215","tag_type":"brand","value":"Adcetris","value_numeric":null},{"paper_doi":"10.1002/hon.70215","tag_type":"brand","value":"Opdivo","value_numeric":null},{"paper_doi":"10.1002/hon.70215","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1002/hon.70215","tag_type":"condition","value":"Classical Hodgkin Lymphoma","value_numeric":null},{"paper_doi":"10.1002/hon.70215","tag_type":"generic","value":"brentuximab vedotin","value_numeric":null},{"paper_doi":"10.1002/hon.70215","tag_type":"generic","value":"nivolumab","value_numeric":null},{"paper_doi":"10.1002/hon.70215","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1002/hon.70215","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1002/hon.70215","tag_type":"modality","value":"Antibody-Drug Conjugate","value_numeric":null},{"paper_doi":"10.1002/hon.70215","tag_type":"modality","value":"PD-1 Inhibitor","value_numeric":null},{"paper_doi":"10.1002/hon.70215","tag_type":"sample_size","value":"n=568","value_numeric":568},{"paper_doi":"10.1002/hon.70215","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1002/hon.70215","tag_type":"study_design","value":"Systematic Review and Meta-Analysis","value_numeric":null},{"paper_doi":"10.1002/hon.70215","tag_type":"warning","value":"Sex distribution across included studies is not reported in the abstract; the 'mixed' sex tag is assumed based on typical cHL trial enrollment.","value_numeric":null},{"paper_doi":"10.1002/hon.70215","tag_type":"warning","value":"The 2-year PFS confidence interval (45–83%) is very wide, limiting precision of the pooled estimate.","value_numeric":null},{"paper_doi":"10.1002/hon.70215","tag_type":"warning","value":"The nivolumab vs. BV comparison is indirect with significant heterogeneity — no head-to-head trial data are available; results should be interpreted cautiously.","value_numeric":null}],"summaries":{"what_studied":"Systematic review and meta-analysis evaluating the efficacy and safety of novel-agent–based frontline regimens (Brentuximab Vedotin and PD-1 inhibitors) in patients aged ≥ 60 years with classical Hodgkin lymphoma (cHL), pooling data from 11 studies (n=568).","key_result":"Pooled complete response (CR) rate was 71% (95% CI: 57–81%) and pooled 2-year PFS was 66% (95% CI: 45–83%). In indirect subgroup comparisons, nivolumab-based regimens showed higher response rates and PFS than BV-based regimens, with lower rates of treatment discontinuation, Grade ≥ 3 infections, and neuropathy.","limitations":"- All comparisons between nivolumab- and BV-based regimens are indirect, with marked heterogeneity across studies.\n- Only 11 studies with 568 patients were included, likely reflecting the underrepresentation of older adults in clinical trials.\n- Differences in outcomes may reflect study design and patient selection rather than true treatment effects.","practice_takeaway":"Novel-agent–based frontline regimens offer better efficacy and tolerability than traditional chemotherapy in older adults (≥60) with cHL. Nivolumab-based regimens appear to be a particularly favorable option, but direct comparative trials are needed before firm preference recommendations can be made."}},{"doi":"10.1016/s2352-3026(26)00068-2","pmid":"42069408","title":"Very early [18F]FDG-PET-guided targeted therapy in untreated advanced-stage classic Hodgkin lymphoma (EORTC-1537-COBRA): primary results of a single-arm, multicentre, phase 2 trial","journal_title":"The Lancet Haematology","journal_issn":"2352-3026","published_at":"2026-05-03T00:00:00.000Z","url":"https://doi.org/10.1016/s2352-3026(26)00068-2","source_score":16,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2026-05-06","doi":"10.1016/s2352-3026(26)00068-2","days":"14","issn":"2352-3026","rank":"10","field":"Clinical Medicine","score":"16","category":"Hematology","categories":["Hematology"],"_categories":["Hematology"]},"pubmed":{"doi":"10.1016/S2352-3026(26)00068-2","title":"Very early [","journal":"The Lancet. Haematology","methods":"","results":"","abstract":"$30","keywords":[],"pubmed_id":"42069408","conclusions":"","publication_date":"2026-05-03T00:00:00"},"crossref":{"DOI":"10.1016/s2352-3026(26)00068-2","URL":"https://doi.org/10.1016/s2352-3026(26)00068-2","ISSN":["2352-3026"],"link":[{"URL":"https://api.elsevier.com/content/article/PII:S2352302626000682?httpAccept=text/xml","content-type":"text/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://api.elsevier.com/content/article/PII:S2352302626000682?httpAccept=text/plain","content-type":"text/plain","content-version":"vor","intended-application":"text-mining"}],"page":"e274-e283","type":"journal-article","issue":"5","score":1,"title":["Very early [18F]FDG-PET-guided targeted therapy in untreated advanced-stage classic Hodgkin lymphoma (EORTC-1537-COBRA): primary results of a single-arm, multicentre, phase 2 trial"],"author":[{"given":"Martin","family":"Hutchings","sequence":"first","affiliation":[]},{"given":"Arjan","family":"Diepstra","sequence":"additional","affiliation":[]},{"given":"Anna","family":"Sureda Balari","sequence":"additional","affiliation":[]},{"given":"Susana","family":"Carvalho","sequence":"additional","affiliation":[]},{"given":"Andrej","family":"Vranovsky","sequence":"additional","affiliation":[]},{"given":"Walter","family":"Noordzij","sequence":"additional","affiliation":[]},{"given":"Annika","family":"Loft","sequence":"additional","affiliation":[]},{"given":"Anne","family":"Arens","sequence":"additional","affiliation":[]},{"given":"Sophie","family":"Teesink","sequence":"additional","affiliation":[]},{"given":"Lydia","family":"Visser","sequence":"additional","affiliation":[]},{"given":"Wendy","family":"Stevens","sequence":"additional","affiliation":[]},{"given":"Berthe M P","family":"Aleman","sequence":"additional","affiliation":[]},{"given":"F J Sherida H","family":"Woei-A-Jin","sequence":"additional","affiliation":[]},{"given":"Maria","family":"Viguria","sequence":"additional","affiliation":[]},{"given":"Kirsten","family":"Saevels","sequence":"additional","affiliation":[]},{"given":"Liane","family":"Te Boome","sequence":"additional","affiliation":[]},{"given":"Sanne","family":"Tonino","sequence":"additional","affiliation":[]},{"given":"Paul","family":"Meijnders","sequence":"additional","affiliation":[]},{"given":"Eva","family":"Domingo Domènech","sequence":"additional","affiliation":[]},{"given":"Caroline","family":"Hasselbalch Riley","sequence":"additional","affiliation":[]},{"given":"Laure","family":"Musekera","sequence":"additional","affiliation":[]},{"given":"Sarah","family":"Nuyens","sequence":"additional","affiliation":[]},{"given":"Cedric","family":"Mallien","sequence":"additional","affiliation":[]},{"given":"Ward","family":"Sents","sequence":"additional","affiliation":[]},{"given":"Emanuel","family":"Bührer","sequence":"additional","affiliation":[]},{"given":"Catherine","family":"Fortpied","sequence":"additional","affiliation":[]},{"given":"Wouter J","family":"Plattel","sequence":"additional","affiliation":[]}],"funder":[{"id":[{"id":"10.13039/100011957","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100011957","name":"Takeda Oncology","doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/501100004897","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100004897","name":"European Organisation for Research and Treatment of Cancer","doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2026,5]]},"member":"78","prefix":"10.1016","source":"Crossref","volume":"13","created":{"date-time":"2026-05-01T01:47:53Z","timestamp":1777600073000,"date-parts":[[2026,5,1]]},"indexed":{"date-time":"2026-05-04T08:31:34Z","timestamp":1777883494491,"date-parts":[[2026,5,4]]},"license":[{"URL":"https://www.elsevier.com/tdm/userlicense/1.0/","start":{"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000,"date-parts":[[2026,5,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://www.elsevier.com/legal/tdmrep-license","start":{"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000,"date-parts":[[2026,5,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://doi.org/10.15223/policy-017","start":{"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000,"date-parts":[[2026,5,1]]},"delay-in-days":0,"content-version":"stm-asf"},{"URL":"https://doi.org/10.15223/policy-037","start":{"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000,"date-parts":[[2026,5,1]]},"delay-in-days":0,"content-version":"stm-asf"},{"URL":"https://doi.org/10.15223/policy-012","start":{"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000,"date-parts":[[2026,5,1]]},"delay-in-days":0,"content-version":"stm-asf"},{"URL":"https://doi.org/10.15223/policy-029","start":{"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000,"date-parts":[[2026,5,1]]},"delay-in-days":0,"content-version":"stm-asf"},{"URL":"https://doi.org/10.15223/policy-004","start":{"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000,"date-parts":[[2026,5,1]]},"delay-in-days":0,"content-version":"stm-asf"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://linkinghub.elsevier.com/retrieve/pii/S2352302626000682"}},"subtitle":[],"assertion":[{"name":"publisher","label":"This article is maintained by","value":"Elsevier"},{"name":"articletitle","label":"Article Title","value":"Very early [18F]FDG-PET-guided targeted therapy in untreated advanced-stage classic Hodgkin lymphoma (EORTC-1537-COBRA): primary results of a single-arm, multicentre, phase 2 trial"},{"name":"journaltitle","label":"Journal Title","value":"The Lancet Haematology"},{"name":"articlelink","label":"CrossRef DOI link to publisher maintained version","value":"https://doi.org/10.1016/S2352-3026(26)00068-2"},{"name":"content_type","label":"Content Type","value":"article"},{"name":"copyright","label":"Copyright","value":"© 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies."}],"deposited":{"date-time":"2026-05-01T01:47:57Z","timestamp":1777600077000,"date-parts":[[2026,5,1]]},"issn-type":[{"type":"print","value":"2352-3026"}],"published":{"date-parts":[[2026,5]]},"publisher":"Elsevier BV","reference":[{"DOI":"10.1038/ncponc1186","key":"10.1016/S2352-3026(26)00068-2_bib1","year":"2008","issue":null,"author":"Evens","volume":"5","first-page":"543","unstructured":null,"article-title":"Treatment of Hodgkin lymphoma: the past, present, and future","journal-title":"Nat Clin Pract Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood-2005-06-2252","key":"10.1016/S2352-3026(26)00068-2_bib2","year":"2006","issue":null,"author":"Hutchings","volume":"107","first-page":"52","unstructured":null,"article-title":"FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1200/JCO.2007.11.6525","key":"10.1016/S2352-3026(26)00068-2_bib3","year":"2007","issue":null,"author":"Gallamini","volume":"25","first-page":"3746","unstructured":null,"article-title":"Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study","journal-title":"J Clin Oncol","doi-asserted-by":"crossref"},{"DOI":"10.2967/jnumed.108.057190","key":"10.1016/S2352-3026(26)00068-2_bib4","year":"2009","issue":"suppl 1","author":"Hutchings","volume":"50","first-page":"21S","unstructured":null,"article-title":"PET/CT for therapy response assessment in lymphoma","journal-title":"J Nucl Med","doi-asserted-by":"crossref"},{"DOI":"10.1200/JCO.2013.53.2838","key":"10.1016/S2352-3026(26)00068-2_bib5","year":"2014","issue":null,"author":"Hutchings","volume":"32","first-page":"2705","unstructured":null,"article-title":"In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma","journal-title":"J Clin Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa1510093","key":"10.1016/S2352-3026(26)00068-2_bib6","year":"2016","issue":null,"author":"Johnson","volume":"374","first-page":"2419","unstructured":null,"article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(17)32134-7","key":"10.1016/S2352-3026(26)00068-2_bib7","year":"2017","issue":null,"author":"Borchmann","volume":"390","first-page":"2790","unstructured":null,"article-title":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1016/S1470-2045(18)30784-8","key":"10.1016/S2352-3026(26)00068-2_bib8","year":"2019","issue":null,"author":"Casasnovas","volume":"20","first-page":"202","unstructured":null,"article-title":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study","journal-title":"Lancet Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1200/JCO.23.01177","key":"10.1016/S2352-3026(26)00068-2_bib9","year":"2024","issue":null,"author":"Luminari","volume":"42","first-page":"13","unstructured":null,"article-title":"Long-term follow-up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial","journal-title":"J Clin Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.2019000719","key":"10.1016/S2352-3026(26)00068-2_bib10","year":"2019","issue":null,"author":"Stephens","volume":"134","first-page":"1238","unstructured":null,"article-title":"Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1200/JCO.2017.75.2543","key":"10.1016/S2352-3026(26)00068-2_bib11","year":"2018","issue":null,"author":"Gallamini","volume":"36","first-page":"454","unstructured":null,"article-title":"Early chemotherapy intensification with escalated beacopp in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two abvd cycles: long-term results of the GITIL/FIL HD 0607 Trial","journal-title":"J Clin Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa1708984","key":"10.1016/S2352-3026(26)00068-2_bib12","year":"2018","issue":null,"author":"Connors","volume":"378","first-page":"331","unstructured":null,"article-title":"Brentuximab Vedotin with Chemotherapy for Stage III or intravenously Hodgkin's Lymphoma","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa2206125","key":"10.1016/S2352-3026(26)00068-2_bib13","year":"2022","issue":null,"author":"Ansell","volume":"387","first-page":"310","unstructured":null,"article-title":"Overall Survival with Brentuximab Vedotin in Stage III or intravenously Hodgkin's Lymphoma","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(24)01315-1","key":"10.1016/S2352-3026(26)00068-2_bib14","year":"2024","issue":null,"author":"Borchmann","volume":"404","first-page":"341","unstructured":null,"article-title":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.2019003127","key":"10.1016/S2352-3026(26)00068-2_bib15","year":"2020","issue":null,"author":"Straus","volume":"135","first-page":"735","unstructured":null,"article-title":"Brentuximab vedotin with chemotherapy for stage III/intravenously classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1200/JCO.2013.53.5229","key":"10.1016/S2352-3026(26)00068-2_bib16","year":"2014","issue":null,"author":"Barrington","volume":"32","first-page":"3048","unstructured":null,"article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","journal-title":"J Clin Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ijrobp.2013.05.005","key":"10.1016/S2352-3026(26)00068-2_bib17","year":"2014","issue":null,"author":"Specht","volume":"89","first-page":"854","unstructured":null,"article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG)","journal-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"crossref"},{"DOI":"10.3324/haematol.2011.053199","key":"10.1016/S2352-3026(26)00068-2_bib18","year":"2012","issue":null,"author":"Plattel","volume":"97","first-page":"410","unstructured":null,"article-title":"Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma","journal-title":"Haematologica","doi-asserted-by":"crossref"},{"DOI":"10.1200/JCO.2013.54.8800","key":"10.1016/S2352-3026(26)00068-2_bib19","year":"2014","issue":null,"author":"Cheson","volume":"32","first-page":"3059","unstructured":null,"article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","journal-title":"J Clin Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1093/annonc/mdx097","key":"10.1016/S2352-3026(26)00068-2_bib20","year":"2017","issue":null,"author":"Younes","volume":"28","first-page":"1436","unstructured":null,"article-title":"International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)","journal-title":"Ann Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S2352-3026(21)00102-2","key":"10.1016/S2352-3026(26)00068-2_bib21","year":"2021","issue":null,"author":"Straus","volume":"8","first-page":"e410","unstructured":null,"article-title":"Brentuximab vedotin with chemotherapy for stage III or intravenously classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial","journal-title":"Lancet Haematol","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa2405888","key":"10.1016/S2352-3026(26)00068-2_bib22","year":"2024","issue":null,"author":"Herrera","volume":"391","first-page":"1379","unstructured":null,"article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin's lymphoma","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1002/hem3.70205","key":"10.1016/S2352-3026(26)00068-2_bib23","year":"2025","issue":null,"author":"Plattel","volume":"9","first-page":null,"unstructured":null,"article-title":"Serum TARC dynamics during anti-PD1-based first-line Hodgkin lymphoma treatment: an analysis from the GHSG NIVAHL trial","journal-title":"HemaSphere","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjh.16514","key":"10.1016/S2352-3026(26)00068-2_bib24","year":"2020","issue":null,"author":"Plattel","volume":"190","first-page":"40","unstructured":null,"article-title":"Interim thymus and activation regulated chemokine versus interim 18 F-fluorodeoxyglucose positron-emission tomography in classical Hodgkin lymphoma response evaluation","journal-title":"Br J Haematol","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41375-022-01717-8","key":"10.1016/S2352-3026(26)00068-2_bib25","year":"2022","issue":null,"author":"Driessen","volume":"36","first-page":"2853","unstructured":null,"article-title":"Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP","journal-title":"Leukemia","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.2024027355","key":"10.1016/S2352-3026(26)00068-2_bib26","year":"2025","issue":null,"author":"Pirosa","volume":"146","first-page":"1207","unstructured":null,"article-title":"A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41586-023-06903-x","key":"10.1016/S2352-3026(26)00068-2_bib27","year":"2024","issue":null,"author":"Alig","volume":"625","first-page":"778","unstructured":null,"article-title":"Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling","journal-title":"Nature","doi-asserted-by":"crossref"}],"short-title":[],"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"update-policy":"https://doi.org/10.1016/elsevier_cm_policy","alternative-id":["S2352302626000682"],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"original-title":[],"container-title":["The Lancet Haematology"],"published-print":{"date-parts":[[2026,5]]},"reference-count":27,"published-online":null,"references-count":27,"short-container-title":["The Lancet Haematology"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1016/s2352-3026(26)00068-2","is_oa":false,"title":"Very early [18F]FDG-PET-guided targeted therapy in untreated advanced-stage classic Hodgkin lymphoma (EORTC-1537-COBRA): primary results of a single-arm, multicentre, phase 2 trial","updated":"2026-05-05T11:59:32+00:00","published_date":"2026-05-01","best_oa_location":null}},"created_at":"2026-05-13T13:19:27.102Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1016/s2352-3026(26)00068-2","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00068-2","tag_type":"brand","value":"Adcetris","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00068-2","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00068-2","tag_type":"condition","value":"Classic Hodgkin Lymphoma","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00068-2","tag_type":"generic","value":"brentuximab vedotin","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00068-2","tag_type":"generic","value":"cyclophosphamide","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00068-2","tag_type":"generic","value":"dacarbazine","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00068-2","tag_type":"generic","value":"dexamethasone","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00068-2","tag_type":"generic","value":"doxorubicin","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00068-2","tag_type":"generic","value":"etoposide","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00068-2","tag_type":"generic","value":"vinblastine","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00068-2","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00068-2","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00068-2","tag_type":"modality","value":"Antibody-Drug Conjugate","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00068-2","tag_type":"modality","value":"Combination Chemotherapy","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00068-2","tag_type":"modality","value":"PET-Guided Adaptive Therapy","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00068-2","tag_type":"sample_size","value":"n=150","value_numeric":150},{"paper_doi":"10.1016/s2352-3026(26)00068-2","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00068-2","tag_type":"study_design","value":"Single-Arm Phase 2 Trial","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00068-2","tag_type":"warning","value":"Funded by Takeda Oncology (manufacturer of brentuximab vedotin); potential industry bias should be considered.","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00068-2","tag_type":"warning","value":"Single-arm design: no randomized comparator, so the 2-year mPFS of 89.5% cannot be directly attributed to the adaptive strategy versus A-AVD alone.","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00068-2","tag_type":"warning","value":"The 80% confidence interval (not the conventional 95%) was used for the primary endpoint, which may widen uncertainty for typical clinical interpretation.","value_numeric":null},{"paper_doi":"10.1016/s2352-3026(26)00068-2","tag_type":"warning","value":"The 'impact_flag' of practice_changing is applied cautiously — this is a phase 2 trial and randomized confirmation is needed before routine adoption.","value_numeric":null}],"summaries":{"what_studied":"This single-arm, phase 2 trial (EORTC-1537-COBRA) evaluated very early [18F]FDG-PET-guided treatment adaptation in 150 adults (aged 18–60) with previously untreated advanced-stage classic Hodgkin lymphoma: after one cycle of A-AVD, PET1-negative patients continued A-AVD (5 more cycles) while PET1-positive patients switched to 6 cycles of BrECADD, with a primary endpoint of 2-year modified progression-free survival (mPFS).","key_result":"At a median follow-up of 30.1 months, the estimated 2-year mPFS was 89.5% (80% CI 85.7–92.4%), with only 16 mPFS events among 145 evaluable patients; 60% of patients were PET1-negative and spared intensification. Grade 3–4 neutropenia occurred in 35% of patients; no deaths were reported.","limitations":"Single-arm design with no randomized comparator limits causal inference. The trial enrolled a relatively young cohort (median age 32 years), restricting generalizability to older patients. Median follow-up of ~30 months may be insufficient to capture late relapses or long-term toxicity.","practice_takeaway":"Very early PET assessment after just one cycle of A-AVD can identify patients who need intensification to BrECADD, achieving high disease control while sparing 60% of patients from more intensive chemotherapy. Clinicians managing advanced-stage classic Hodgkin lymphoma may consider this adaptive strategy, pending randomized confirmation."}},{"doi":"10.1182/bloodadvances.2025018455","pmid":"41707114","title":"Patterns of care and clinical outcomes in systemic peripheral T-cell lymphoma: the LEO-MER prospective cohort study","journal_title":"Blood Advances","journal_issn":"2473-9529","published_at":"2026-02-18T00:00:00.000Z","url":"https://doi.org/10.1182/bloodadvances.2025018455","source_score":26,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-18T13:25:41.443Z","updated_at":"2026-05-18T13:25:41.443Z","tags":[{"paper_doi":"10.1182/bloodadvances.2025018455","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018455","tag_type":"brand","value":"Adcetris","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018455","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018455","tag_type":"condition","value":"Anaplastic Large-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018455","tag_type":"condition","value":"Peripheral T-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018455","tag_type":"generic","value":"brentuximab vedotin","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018455","tag_type":"generic","value":"CHOP","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018455","tag_type":"generic","value":"etoposide","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018455","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018455","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018455","tag_type":"modality","value":"Antibody-Drug Conjugate","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018455","tag_type":"modality","value":"Autologous Stem Cell Transplant","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018455","tag_type":"modality","value":"Chemotherapy","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018455","tag_type":"sample_size","value":"n=720","value_numeric":720},{"paper_doi":"10.1182/bloodadvances.2025018455","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018455","tag_type":"study_design","value":"Prospective Cohort Study","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018455","tag_type":"warning","value":"BV-CHP represented only 5% of the cohort (roughly 36 patients), so the trend toward OS benefit in ALCL is underpowered and should be interpreted cautiously.","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018455","tag_type":"warning","value":"Level of evidence assigned as 2 given prospective design, but observational (non-randomized) nature limits causal conclusions.","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025018455","tag_type":"warning","value":"The MER cohort spans 2002–2015, meaning some patients received regimens no longer considered standard; treatment-era heterogeneity may affect outcome estimates.","value_numeric":null}],"summaries":{"what_studied":"Two linked prospective cohort studies (LEO 2015–2020, MER 2002–2015, both followed to 2024) enrolled 720 adults with systemic PTCL to characterize real-world first-line treatment patterns and outcomes, with EFS and OS as primary endpoints.","key_result":"CHOP-based regimens dominated first-line therapy (70%); only 14% received consolidative auto-SCT. Patients failing EFS6 had a 5-year subsequent OS of just 12%; those failing EFS24 had 17%. Adding etoposide to CHOP improved OS in ALK-negative ALCL; BV-CHP showed a trend toward OS benefit in ALCL. Non-ALCL subtypes and higher IPI/PIT scores carried significantly worse EFS and OS.","limitations":"BV-CHP use was only 5% of the cohort, limiting power for that subgroup analysis. The MER cohort spans back to 2002, introducing treatment-era heterogeneity. Observational design prevents causal inference.","practice_takeaway":"For ALK-negative ALCL, adding etoposide to CHOP or using BV-CHP appears beneficial and should be considered. Patients with non-ALCL PTCL who fail early (EFS6/EFS24) have dire outcomes, making enrollment in targeted therapy trials a priority for this group."}},{"doi":"10.1111/ddg.15897","pmid":"41025752","title":"Brentuximab vedotin and radiotherapy for CD30‐positive cutaneous T‐cell lymphoma – a retrospective multicenter analysis","journal_title":"JDDG: Journal der Deutschen Dermatologischen Gesellschaft","journal_issn":"1610-0379","published_at":"2025-09-30T00:00:00.000Z","url":"https://doi.org/10.1111/ddg.15897","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-10-01","doi":"10.1111/ddg.15897","days":"14","issn":"1610-0379","rank":"10","field":"Clinical Medicine","score":"7","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1111/ddg.15897","title":"Brentuximab vedotin and radiotherapy for CD30-positive cutaneous T-cell lymphoma - a retrospective multicenter analysis.","journal":"Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG","methods":"","results":"Adverse events of any grade occurred in 71% of patients, most commonly peripheral neuropathy, neutropenia, and radiodermatitis. Thirteen patients achieved a complete or partial remission as best overall response, however, 50% of all patients showed disease progression. At a median follow-up of 14.4 months, median progression-free survival was 12.0 months, with a 1-year rate of 34.0%.","abstract":"$31","keywords":["Brentuximab vedotin","cutaneous T‐cell lymphoma","radiotherapy"],"pubmed_id":"41025752","conclusions":"","publication_date":"2025-09-30T00:00:00"},"crossref":{"DOI":"10.1111/ddg.15897","URL":"https://doi.org/10.1111/ddg.15897","ISSN":["1610-0379","1610-0387"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/ddg.15897","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Brentuximab vedotin and radiotherapy for CD30‐positive cutaneous T‐cell lymphoma – a retrospective multicenter analysis"],"author":[{"given":"Patrick","family":"Schummer","sequence":"first","affiliation":[{"name":"Department of Dermatology Venereology and Allergology University Hospital Würzburg Würzburg Germany"}]},{"given":"Caroline","family":"Glatzel","sequence":"additional","affiliation":[{"name":"Department of Dermatology Venereology and Allergology University Hospital Würzburg Würzburg Germany"}]},{"given":"Philipp","family":"Schrüfer","sequence":"additional","affiliation":[{"name":"Department of Dermatology Venereology and Allergology University Hospital Würzburg Würzburg Germany"},{"name":"Skinmed AG Lenzburg Switzerland"}]},{"given":"Ingulf","family":"Lawrenz","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Radiooncology University Hospital Würzburg Würzburg Germany"}]},{"given":"Gabor","family":"Dobos","sequence":"additional","affiliation":[{"name":"Department of Dermatology Venereology and Allergology Charité – Universitätsmedizin Berlin Berlin Germany"}]},{"given":"Ulrike","family":"Wehkamp","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy University Hospital Schleswig‐Holstein Kiel Germany"},{"name":"Medical School Hamburg Hamburg Germany"}]},{"given":"Svea","family":"Hüning","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital of Dortmund Dortmund Germany"},{"name":"Hautarztpraxis Schwelm Schwelm Germany"}]},{"given":"René","family":"Stranzenbach","sequence":"additional","affiliation":[{"name":"Dermatologie‐Gevelsberg Gevelsberg Germany"}]},{"given":"Jan P.","family":"Nicolay","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Medical Center Mannheim Mannheim Germany"}]},{"given":"Matthias","family":"Goebeler","sequence":"additional","affiliation":[{"name":"Department of Dermatology Venereology and Allergology University Hospital Würzburg Würzburg Germany"}]},{"given":"Marion","family":"Wobser","sequence":"additional","affiliation":[{"name":"Department of Dermatology Venereology and Allergology University Hospital Würzburg Würzburg Germany"}]}],"issued":{"date-parts":[[2025,9,30]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":null,"archive":["Portico"],"created":{"date-time":"2025-09-30T12:50:01Z","timestamp":1759236601000,"date-parts":[[2025,9,30]]},"indexed":{"date-time":"2025-10-01T15:57:00Z","timestamp":1759334220461,"date-parts":[[2025,10,1]]},"license":[{"URL":"http://creativecommons.org/licenses/by/4.0/","start":{"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000,"date-parts":[[2025,9,30]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":"$32","language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/ddg.15897"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-02-28"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-06-16"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2025-09-30"}],"deposited":{"date-time":"2025-09-30T12:50:05Z","timestamp":1759236605000,"date-parts":[[2025,9,30]]},"issn-type":[{"type":"print","value":"1610-0379"},{"type":"electronic","value":"1610-0387"}],"published":{"date-parts":[[2025,9,30]]},"publisher":"Wiley","reference":[{"DOI":"10.1002/hon.2850","key":"e_1_2_8_2_1","year":"2021","issue":"1","author":"Kempf W","volume":"39","first-page":"46","unstructured":null,"article-title":"Cutaneous T‐cell lymphomas‐An update 2021","journal-title":"Hematol Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1093/annonc/mdy133","key":"e_1_2_8_3_1","year":"2018","issue":"4","author":"Willemze R","volume":"29","first-page":"iv30","unstructured":null,"article-title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up","journal-title":"Ann Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(17)31266-7","key":"e_1_2_8_4_1","year":"2017","issue":"10094","author":"Prince HM","volume":"390","first-page":"555","unstructured":null,"article-title":"Brentuximab vedotin or physician's choice in CD30‐positive cutaneous T‐cell lymphoma (ALCANZA): an international, open‐label, randomised, phase 3, multicentre trial","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1182/bloodadvances.2021004710","key":"e_1_2_8_5_1","year":"2021","issue":"23","author":"Horwitz SM","volume":"5","first-page":"5098","unstructured":null,"article-title":"Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T‐cell lymphoma: final data","journal-title":"Blood Adv","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ijrobp.2015.01.008","key":"e_1_2_8_6_1","year":"2015","issue":"1","author":"Specht L","volume":"92","first-page":"32","unstructured":null,"article-title":"Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group","journal-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.det.2015.05.006","key":"e_1_2_8_7_1","year":"2015","issue":"4","author":"Tandberg DJ","volume":"33","first-page":"703","unstructured":null,"article-title":"Radiation Therapy for Cutaneous T‐Cell Lymphomas","journal-title":"Dermatol Clin","doi-asserted-by":"crossref"},{"DOI":"10.1002/ajh.26299","key":"e_1_2_8_8_1","year":"2021","issue":"10","author":"Hristov AC","volume":"96","first-page":"1313","unstructured":null,"article-title":"Cutaneous T‐cell lymphomas: 2021 update on diagnosis, risk‐stratification, and management","journal-title":"Am J Hematol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ejca.2024.115064","key":"e_1_2_8_9_1","year":"2024","issue":null,"author":"Elsayad K","volume":"212","first-page":null,"unstructured":null,"article-title":"Radiotherapy in cutaneous lymphomas: Recommendations from the EORTC cutaneous lymphoma tumour group","journal-title":"Eur J Cancer","doi-asserted-by":"crossref"},{"DOI":"10.1111/dth.13478","key":"e_1_2_8_10_1","year":"2020","issue":"4","author":"Georgakopoulos I","volume":"33","first-page":null,"unstructured":null,"article-title":"Low dose total skin electron beam therapy for the management of T cell cutaneous lymphomas","journal-title":"Dermatol Ther","doi-asserted-by":"crossref"},{"DOI":null,"key":"e_1_2_8_11_1","year":"2020","issue":"15","author":"Song S","volume":"38","first-page":null,"unstructured":null,"article-title":"Phase Ib study of brentuximab vedotin (BV) with low‐dose total skin electron beam (LD‐TSEB) for treatment of mycosis fungoides (MF) and Sezary syndrome (SS)","journal-title":"J Clin Oncol","doi-asserted-by":null},{"DOI":"10.1002/ajh.23925","key":"e_1_2_8_12_1","year":"2015","issue":"4","author":"Dozzo M","volume":"90","first-page":"E73","unstructured":null,"article-title":"Brentuximab vedotin in combination with extended field radiotherapy as salvage treatment for primary refractory Hodgkin lymphoma","journal-title":"Am J Hematol","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood-2016-03-703470","key":"e_1_2_8_13_1","year":"2016","issue":"11","author":"Kumar A","volume":"128","first-page":"1458","unstructured":null,"article-title":"Brentuximab vedotin and AVD followed by involved‐site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1159/000479224","key":"e_1_2_8_14_1","year":"2017","issue":"3","author":"Montana W","volume":"10","first-page":"795","unstructured":null,"article-title":"Near Complete Response in a Patient with Classical Hodgkin Lymphoma Treated with Brentuximab Vedotin Concurrent with Radiation Therapy","journal-title":"Case Rep Oncol","doi-asserted-by":"crossref"},{"DOI":"10.14740/jh534","key":"e_1_2_8_15_1","year":"2019","issue":"3","author":"Floyd EG","volume":"8","first-page":"132","unstructured":null,"article-title":"Combined Modality Treatment With Brentuximab Vedotin and Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: A Case Report","journal-title":"J Hematol","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood-2007-03-055749","key":"e_1_2_8_16_1","year":"2007","issue":"6","author":"Olsen E","volume":"110","first-page":"1713","unstructured":null,"article-title":"Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1093/bjd/ljac012","key":"e_1_2_8_17_1","year":"2023","issue":"1","author":"Oymanns M","volume":"188","first-page":"145","unstructured":null,"article-title":"Near complete responses to concurrent brentuximab vedotin and ultra‐hypofractionated low‐dose total skin electron beam radiation in advanced cutaneous T‐cell lymphoma","journal-title":"The British journal of dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1158/0008-5472.CAN-14-1931","key":"e_1_2_8_18_1","year":"2015","issue":"7","author":"Buckel L","volume":"75","first-page":"1376","unstructured":null,"article-title":"Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery","journal-title":"Cancer Res","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.adro.2023.101279","key":"e_1_2_8_19_1","year":"2023","issue":"6","author":"Wu SY","volume":"8","first-page":null,"unstructured":null,"article-title":"Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma","journal-title":"Adv Radiat Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1111/jdv.18563","key":"e_1_2_8_20_1","year":"2023","issue":"1","author":"Muniesa C","volume":"37","first-page":"57","unstructured":null,"article-title":"Brentuximab vedotin in the treatment of cutaneous T‐cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"crossref"},{"DOI":"10.1111/ddg.14342","key":"e_1_2_8_21_1","year":"2021","issue":"3","author":"Stranzenbach R","volume":"19","first-page":"383","unstructured":null,"article-title":"Combination of brentuximab‐vedotin with skin‐directed therapies extends the time to the next therapeutic line in patients with cutaneous T‐cell lymphoma","journal-title":"J Dtsch Dermatol Ges","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ijrobp.2024.11.011","key":"e_1_2_8_22_1","year":"2025","issue":"4","author":"Elsayad K","volume":"121","first-page":"1006","unstructured":null,"article-title":"Real‐World Pattern‐of‐Care Analysis of Primary Cutaneous Lymphomas Radiation Therapy Among European Organisation for Research and Treatment of Cancer Members","journal-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"crossref"}],"short-title":[],"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/ddg.15897"],"article-number":"ddg.15897","content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"reference-count":21,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,9,30]]},"references-count":21,"short-container-title":["J Deutsche Derma Gesell"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1111/ddg.15897","is_oa":true,"title":"Brentuximab vedotin and radiotherapy for CD30‐positive cutaneous T‐cell lymphoma – a retrospective multicenter analysis","updated":"2025-10-03T07:17:10+00:00","published_date":"2025-09-30","best_oa_location":{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ddg.15897","pmh_id":null,"url_for_pdf":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ddg.15897","url_for_landing_page":"https://doi.org/10.1111/ddg.15897"}}},"created_at":"2025-10-11T07:13:56.506Z","updated_at":"2025-10-15T07:01:11.375Z","tags":[{"paper_doi":"10.1111/ddg.15897","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1111/ddg.15897","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1111/ddg.15897","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/ddg.15897","tag_type":"condition","value":"Cutaneous T-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1111/ddg.15897","tag_type":"generic","value":"brentuximab vedotin","value_numeric":null},{"paper_doi":"10.1111/ddg.15897","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1111/ddg.15897","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1111/ddg.15897","tag_type":"modality","value":"Antibody-Drug Conjugate","value_numeric":null},{"paper_doi":"10.1111/ddg.15897","tag_type":"modality","value":"Radiotherapy","value_numeric":null},{"paper_doi":"10.1111/ddg.15897","tag_type":"sample_size","value":"n=14","value_numeric":14},{"paper_doi":"10.1111/ddg.15897","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1111/ddg.15897","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1111/ddg.15897","tag_type":"warning","value":"Global response was assessed at BV discontinuation or last follow-up, not at a uniform timepoint; the 1-year PFS confidence interval is very wide due to small N.","value_numeric":null},{"paper_doi":"10.1111/ddg.15897","tag_type":"warning","value":"One patient had a non-MF CTCL subtype with missing staging, adding clinical heterogeneity.","value_numeric":null},{"paper_doi":"10.1111/ddg.15897","tag_type":"warning","value":"Single-arm retrospective series from six centers with heterogeneous radiation doses/schedules and BV modifications; efficacy versus BV alone is uncertain.","value_numeric":null}],"summaries":{"what_studied":"A retrospective multicenter series evaluated 14 patients with CD30‑positive cutaneous T‑cell lymphoma treated with brentuximab vedotin (BV) plus radiotherapy started within 3 months before/after BV or given simultaneously; low‑dose RTx was common (≤12 Gy in 57%). Median follow‑up was 14.4 months.","key_result":"Adverse events occurred in 71% (10/14), with grade ≥3 in 21% (3/14); common events were peripheral neuropathy, neutropenia, and radiodermatitis. Best overall response was CR 14% (2/14) and PR 79% (11/14); at last assessment CR 14%, PR 29%, SD 7%, PD 50%; median PFS was 12.0 months (95% CI 7.3–NA) with 1‑year PFS 34.0% (95% CI 12.9–90.1).","limitations":"Very small sample (n=14) with heterogeneous RTx modalities, doses, and BV adjustments; retrospective, single‑arm design without a control group; predominantly advanced‑stage disease and unsystematic documentation limit generalizability.","practice_takeaway":"Combining BV with RTx (sequentially or concurrently) was feasible and generally well tolerated, with expected toxicities and no new safety signals. Use caution with higher RTx doses and close sequencing, as severe hematologic events were observed with 30 Gy schedules and near‑term BV."}}],"initialOffset":7,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"generic","value":"brentuximab vedotin"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Generics","href":"/hub/tag/generic"},{"name":"brentuximab vedotin"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"generic","hub_tag_value":"brentuximab vedotin"}}}]]

Papers